{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:21:40Z","timestamp":1790274100651,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Thellie endowment fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.antiviral.2020.104869","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T13:39:09Z","timestamp":1595943549000},"page":"104869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Revisiting HBV resistance to entecavir with a phenotypic approach"],"prefix":"10.1016","volume":"181","author":[{"given":"Julien","family":"Marlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Lier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Roch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Maugey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"d\u2019Alteroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Barbereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Causse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bastides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Nadege","family":"Bachelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denys","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gaudy-Graffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104869_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2007.12.024","article-title":"Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response","volume":"48","author":"Baldick","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.22211","article-title":"Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance","volume":"47","author":"Baldick","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib3","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1128\/JVI.00621-06","article-title":"Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity","volume":"80","author":"Blanchet","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104869_bib4","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","article-title":"A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients","volume":"129","author":"Chang","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2020.104869_bib6","first-page":"855","article-title":"A new strategy for studying in Vitro the drug susceptibility of clinical isolates of human hepatitis B virus","volume":"40","author":"David","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-013-0915-1","article-title":"Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy","volume":"47","author":"Deng","year":"2013","journal-title":"Virus Gene."},{"key":"10.1016\/j.antiviral.2020.104869_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3851\/IMP2928","article-title":"Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine","volume":"20","author":"Geipel","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104869_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2018.04.002","article-title":"Trends in hepatitis B virus resistance to nucleoside\/nucleotide analogs in North China from 2009 to 2016: a retrospective study","author":"Guo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.antiviral.2020.104869_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jmv.22260","article-title":"Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy","volume":"84","author":"Hu","year":"2012","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104869_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib13","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/JVI.02395-06","article-title":"Inhibition of hepatitis B virus polymerase by entecavir","volume":"81","author":"Langley","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104869_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2014.02.029","article-title":"Prospective evaluation of FibroTest\u00ae, FibroMeter\u00ae, and HepaScore\u00ae for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C","volume":"61","author":"Leroy","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib15","series-title":"In Vitro Phenotyping of Recombinant Hepatitis B Virus Containing the Polymerase\/Reverse Transcriptase Gene from Clinical Isolates","author":"Liu","year":"2013"},{"key":"10.1016\/j.antiviral.2020.104869_bib16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104869_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/22221751.2019.1584018","article-title":"Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice","volume":"8","author":"Liu","year":"2019","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2020.104869_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhep.2001.26815","article-title":"Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection","volume":"34","author":"Man","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib19","first-page":"3858","article-title":"Growth of human hepatoma cell lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Canc. Res."},{"key":"10.1016\/j.antiviral.2020.104869_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000361076","article-title":"Hepatitis B virus drug resistance tools: one sequence, two predictions","volume":"57","author":"Neumann-Fraune","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2020.104869_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IDR.S4188","article-title":"Safety and efficacy of entecavir for the treatment of chronic hepatitis B","volume":"4","author":"Osborn","year":"2011","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2020.104869_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12876-017-0596-7","article-title":"Comparison of the long-term efficacy between entecavir and tenofovir in treatment- na\u00efve chronic hepatitis B patients","volume":"17","author":"Park","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104869_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104869_bib27","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104869_bib28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104869_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104869_bib32","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3748\/wjg.v21.i25.7869","article-title":"Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis","volume":"21","author":"Xu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104869_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/hep4.1022","article-title":"Resistance mutations of hepatitis B virus in entecavir\u2010refractory patients","volume":"1","author":"Yamada","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.antiviral.2020.104869_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.diagmicrobio.2010.12.009","article-title":"Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients","volume":"70","author":"Yoshitsugu","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:11Z","timestamp":1759062731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S0166354220302837"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104869","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting HBV resistance to entecavir with a phenotypic approach","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104869"}}